KR930016379A - 아릴사이클로알킬 유도체, 이의 제조방법 및 용도 - Google Patents

아릴사이클로알킬 유도체, 이의 제조방법 및 용도 Download PDF

Info

Publication number
KR930016379A
KR930016379A KR1019930000507A KR930000507A KR930016379A KR 930016379 A KR930016379 A KR 930016379A KR 1019930000507 A KR1019930000507 A KR 1019930000507A KR 930000507 A KR930000507 A KR 930000507A KR 930016379 A KR930016379 A KR 930016379A
Authority
KR
South Korea
Prior art keywords
alkyl
compound
formula
compounds
vii
Prior art date
Application number
KR1019930000507A
Other languages
English (en)
Other versions
KR100276933B1 (ko
Inventor
가나파티 나익 라마찬드라
나라얀 뭄바이카 발라스
바수마티 란가라쟌
다우드하이 라크다왈라 아프탑
비탈리오 쉬롤 만다키니
랄 반시
블룸바흐 위르겐
울리히 바이트만 클라우스
리더 바트렛 로베르트
Original Assignee
테르가우, 바이쎄르트
훽스트 아크티엔게젤샤프트
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 테르가우, 바이쎄르트, 훽스트 아크티엔게젤샤프트 filed Critical 테르가우, 바이쎄르트
Publication of KR930016379A publication Critical patent/KR930016379A/ko
Application granted granted Critical
Publication of KR100276933B1 publication Critical patent/KR100276933B1/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
    • C07C49/76—Ketones containing a keto group bound to a six-membered aromatic ring
    • C07C49/82—Ketones containing a keto group bound to a six-membered aromatic ring containing hydroxy groups
    • C07C49/83—Ketones containing a keto group bound to a six-membered aromatic ring containing hydroxy groups polycyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C205/00—Compounds containing nitro groups bound to a carbon skeleton
    • C07C205/45—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by at least one doubly—bound oxygen atom, not being part of a —CHO group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C229/06—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton
    • C07C229/08—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to hydrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/30—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by doubly-bound oxygen atoms
    • C07C233/33—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by doubly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/49—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C255/56—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and doubly-bound oxygen atoms bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C07C45/61—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups
    • C07C45/67—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton
    • C07C45/673—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton by change of size of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C07C45/61—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups
    • C07C45/67—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton
    • C07C45/68—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton by increase in the number of carbon atoms
    • C07C45/72—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton by increase in the number of carbon atoms by reaction of compounds containing >C = O groups with the same or other compounds containing >C = O groups
    • C07C45/74—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton by increase in the number of carbon atoms by reaction of compounds containing >C = O groups with the same or other compounds containing >C = O groups combined with dehydration
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
    • C07C49/76—Ketones containing a keto group bound to a six-membered aromatic ring
    • C07C49/82—Ketones containing a keto group bound to a six-membered aromatic ring containing hydroxy groups
    • C07C49/835—Ketones containing a keto group bound to a six-membered aromatic ring containing hydroxy groups having unsaturation outside an aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
    • C07C49/76—Ketones containing a keto group bound to a six-membered aromatic ring
    • C07C49/84—Ketones containing a keto group bound to a six-membered aromatic ring containing ether groups, groups, groups, or groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C65/00—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C65/32—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing keto groups
    • C07C65/40—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing keto groups containing singly bound oxygen-containing groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D307/40—Radicals substituted by oxygen atoms
    • C07D307/46—Doubly bound oxygen atoms, or two oxygen atoms singly bound to the same carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
    • C07D317/50—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to atoms of the carbocyclic ring
    • C07D317/54—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/22—Radicals substituted by doubly bound hetero atoms, or by two hetero atoms other than halogen singly bound to the same carbon atom

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

본 발명은 염중 상태에 대한 활성을 나타내는 일반식(I)의 화합물을 관한 것이다.
상기식에서 R1은 C1-C6-알킬, 치환된 C1-C6-알킬, C(O)0-C1-C4- 알킬 또는 O(O)OH) 이거나
[여기서, R5는 서로 독립적으로H, C1-C6-알킬, 치환된 C1-C6-알킬, 하이드록시, 카복시, 시아노, -NHC(O)C1-C3-알킬, -O-C1-C3-알킬페닐, -CCH2-O, C1-C6-알콕시, C1-C4-알킬-O-C1-C4-알킬, O-C(O)-C1-C4-알킬, -C(O)-O-C1-C4-알킬, 할로겐, 아미노, 니트로, -NH-C1-C4-알킬, -N-(C1-C4-알킬)2및 -C1-C4- 알킬-R6(여기서, R6은
로부터 선택된 잔기이다)으로부터 선택된 1,2,3 또는 4개의 잔기이며, X는 O,S,N-H 또는 N-C1-C6- 알킬이다]로부터 선택된 잔기이고; R2는 H, C1-C6-알킬 또는 -C(O)-C1-C6-알킬이며; R2은 서로 독립적으로 H, C1-C6-알킬, -C(O)-C1-C6-알킬, -C(O)-O-C1-C6- 알킬, OH, O-C1-C6-알킬, -O-C(O)-C1-C6-알킬 및 할로겐으로부터 선택된 1,2 또는 3개의 잔기이고, R4는 H, -OH, -O-C1-C6-알킬, -O-(CO)-C1-C6-알킬, -C(O)-OH, -C(O) -O-C1-C6알킬,,또는

Description

아릴사이클로알킬 유도체, 이의 제조방법 및 용도
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
제1도는 LPS 자극된 IL-1알파(약IC50=200 내지 300nmoℓ/ℓ의 억제제로서의 화합물(4)의 효과를 나타내었다.

Claims (9)

  1. 하기 일반식(I)의 화합물
    상기식에서 R1은 C1-C6-알킬, 치환된 C1-C6-알킬, C(O)O-C1-C4-알킬 또는 O(O)OH이거나,
    [여기서, R5는 서로 독립적으로 H, C1-C6-알킬, 치환된 C1-C6- 알킬, 하이드록시, 카복시, 시아노, -NHC(O)C1-C3-알킬, -O-C1-C3-알킬페닐, -COH2-O-, C1-C6-알콕시, C1-C4-알킬-O-C1-C4-알킬, O-C(O)-C1-C4-알킬, -C(O)-O-C1-C4-알킬, 할로겐, 아미노 , 니트로, -NH-C1-C4-알킬, -N-(C1-C4-알킬)2및 -C1-C4-알킬-R6(여기서,R6은
    로부터 선택된 잔기이다)으로부터 선택된 1,2,3 또는 4개의 잔기이며, X는 O, S, N-H 또는 N-C1-C6-알킬이다]로부터 선택된 잔기이고; R2는 H, C1-C6-알킬 또는 -C(O)-C1-C6-알킬이며; R3은 서로 독립적으로 H, C1-C6-알킬, -C(O)-C1-C6-알킬,-C(O)-O-C1-C6-알킬, OH, O-C1-C6-알킬,-O-C(O)-C1-C6- 알킬 및 할로겐으로부터 선택된 1, 2 또는 3개의 잔기이고, R4는 H, -OH, -O-C1-C4-알킬,-O-(C0)-C1-C6-알킬, -C(O)-O-C1-C6-알킬,,이며; n은 0, 1 또는 2이고 ; 'a'는 임의의 추가의 단일결합을 타나낸다.
  2. 제1항에 있어서, 하기 일반식(Ⅱ)의 화합물.
    상기식에서, R1, R2, R3, R4및 a는 제1항에서 정의한 바와같다.
  3. 제1항 또는 제2항에 있어서, R1이
    [여기서, R5는 H, C1-C6-알킬, 치환된 C1-C6-알킬, 하이드록시, C1-C3-알콕시, 할로겐 또는 C1-C4-알킬-R6(여기서, R6은
    이다)이며, X는O,NH,S 또는N-C1-C6- 알킬이다)이며;a가 임의의 추가의 결합인 일반식(I)의 화합물.
  4. 제1항 내지 제3항중의 어느 한 항에 있어서, 하기 일반식(Ⅲ)의 화합물.
    상기식에서, R3는 H 또는 C1-C3-알킬이고, R5는 1 또는 2개의 할로겐 또는 1 또는 2개의 C1-C6-알킬 또는 C1-C3-알콕시 그룹이며, a는 임의의 추가의 단일결합이다
  5. A) 일반식(V)의 화합물을 보란-용매-착물로 처리한 다음, 산화시켜, R4가 OH 인 하기 일반식(Ⅵ)의 화합물로 전환시키거나, B) 일반식(V)의 화합물을 과산 및 에폭사이드로 처리한 다음, 수소화물 제제로 처리하여, 일반식(Ⅵ)의 화합물을 수득하거나, C) 적합한 아렌을 산 촉매의 존재하에 사이클로헥센옥사이드와 축합시켜 일반식(Ⅵ)의 화합물을 수득하고, D) 일반식(Ⅵ)의 화합물을 아세트산 무수물과 무기산으로 처리하여, R2가 메틸이고 R4가 O-C(O)-Me인 일반식(Ⅶ)의 화합물을 수득하며, E) D) 에서 기술한 바와같은 일반식(Ⅶ)의 화합물을 루이스산 또는 탈메틸화제로 처리하여 탈메틸화시켜, R2가 H이고 R4가 OC(O)Me인 일반식(Ⅶ)의 화합물을 수득하고, F) E)에서 제조한 화합물을 묽은 알칼리로 처리하여, R2가 H이고 R4가 OH인 일반식(Ⅶ)의 화합물을 수득하며, G) 일반식(Ⅷ)의 화합물을 염기의 존재하에 적절한 알데하이드로 처리하여 a가 추가의 결합인 일반식(Ⅰ)의 화합물로 전환시키고, 이를 수소화시켜 a가 추가의 결합이 아닌 일반식(Ⅰ)의 화합물을 제조함을 특징으로 하여, 일반식(Ⅰ)의 화합물을 제조하는 방법.
    상기식에서 R1, R2, n 및 R은 제1항에 정의한 바와 같다.
  6. 제1항 내지 제4항 중의 어느 한 항에서 청구한 하나 이상의 화합물을 활성 양으로 함유하는 약제.
  7. 염증상태, 특히 만성 염증 상태를 예방하고/거나 치료하기 위한, 제1항 내지 제4항중의 어느 한 항에서 청구한 화합물의 용도.
  8. 염증 상태, 특히 만성 염증 상태에 대해 작용하는 약제를 제조하기 위한, 제1항 내지 제4항 중의 어느 한항에서 청구한 화합물의 용도.
  9. 제1항 내지 제4항 중의 어느 한 항에서 청구한 하나 이상의 화합물을 임의의 약제학적 보조제 및/또는 부형제와 함께 적합한 투여 형태로 제조함을 특징으로 하는, 제6항에서 청구한 약제의 제조방법.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019930000507A 1992-01-16 1993-01-16 아릴사이클로알킬 유도체, 이의 제조방법 및 이를 함유하는 약제학적 조성물 KR100276933B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP92100664 1992-01-16
EP92-100664.9 1992-01-16

Publications (2)

Publication Number Publication Date
KR930016379A true KR930016379A (ko) 1993-08-26
KR100276933B1 KR100276933B1 (ko) 2001-02-01

Family

ID=8209245

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019930000507A KR100276933B1 (ko) 1992-01-16 1993-01-16 아릴사이클로알킬 유도체, 이의 제조방법 및 이를 함유하는 약제학적 조성물

Country Status (19)

Country Link
US (2) US5589514A (ko)
EP (1) EP0551849B1 (ko)
JP (1) JP2949000B2 (ko)
KR (1) KR100276933B1 (ko)
CN (1) CN1036779C (ko)
AT (1) ATE143935T1 (ko)
AU (1) AU662382B2 (ko)
CA (1) CA2087414C (ko)
CZ (1) CZ285937B6 (ko)
DE (1) DE69305189T2 (ko)
DK (1) DK0551849T3 (ko)
ES (1) ES2093860T3 (ko)
GR (1) GR3021338T3 (ko)
HU (1) HU221007B1 (ko)
MX (1) MX9300222A (ko)
RU (1) RU2125553C1 (ko)
SK (1) SK280617B6 (ko)
TW (1) TW376382B (ko)
ZA (1) ZA93267B (ko)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6159988A (en) * 1992-01-16 2000-12-12 Hoeschst Aktiengesellschaft Arylcycloalkyl derivatives, their production and their use
HRP950558A2 (en) * 1994-11-15 1997-12-31 Scott M. Wilhelm Substituted 4-biarylbutric or biarylpentanoic acids and derivatives as matrix metalloprotease inhibitors
ATE298566T1 (de) 1995-09-11 2005-07-15 Osteoarthritis Sciences Inc Proteintyrosine-kinaseinhibitoren zur behandlung der osteoarthritis
BR9803596A (pt) * 1997-09-23 2000-04-25 Pfizer Prod Inc Derivados do resorcinol.
US6878381B2 (en) 1999-03-22 2005-04-12 Pfizer, Inc Resorcinol composition
US6828460B2 (en) 1999-03-22 2004-12-07 Pfizer Inc. Resorcinol derivatives
GB0021776D0 (en) * 2000-09-05 2000-10-18 Arakis Ltd The treatment of inflammatory disorders
UA82827C2 (en) 2000-12-18 2008-05-26 Inhibitors against the production and release of inflammatory cytokines
DE10222895A1 (de) * 2002-05-23 2003-12-11 Bosch Gmbh Robert Hochdruckspeicher für Kraftstoffeinspritzsysteme mit integriertem Druckregelventil
TWI280876B (en) * 2002-06-05 2007-05-11 Inst Med Molecular Design Inc Therapeutic drug for diabetes
TW200410671A (en) * 2002-06-05 2004-07-01 Inst Med Molecular Design Inc Medicines for inhibiting the activation of AP-1
EA008622B1 (ru) * 2002-06-05 2007-06-29 Инститьют Оф Медисинал Молекьюлар Дизайн. Инк. Ингибиторы ассоциированной с иммунитетом протеинкиназы
KR101054562B1 (ko) 2002-06-06 2011-08-04 가부시키가이샤 이야쿠 분지 셋케이 겐쿠쇼 항알레르기약
JP4743382B2 (ja) 2002-06-06 2011-08-10 株式会社医薬分子設計研究所 Ｏ−置換ヒドロキシアリール誘導体
TW200307535A (en) * 2002-06-10 2003-12-16 Inst Med Molecular Design Inc Therapeutic agent for cancer
TW200410675A (en) * 2002-06-10 2004-07-01 Inst Med Molecular Design Inc An NF-κB activation inhibitor
CA2488979A1 (en) * 2002-06-11 2003-12-18 Institute Of Medicinal Molecular Design, Inc. Medicament for treatment of neurodegenerative diseases
KR20050074949A (ko) * 2002-11-12 2005-07-19 엔오케이 가부시키가이샤 고무형상 탄성부품
CA2794676A1 (en) 2010-03-29 2011-10-06 Piramal Enterprises Limited Cytokine inhibitors
EA023852B1 (ru) * 2014-02-12 2016-07-29 Институт Нефтехимических Процессов Им. Академика Ю. Мамедалиева, Нан Азербайджана 2-гидрокси-5-(1-метилциклоалкил)ацетофеноны - стабилизаторы полистирола
EP3386500B1 (en) 2015-12-09 2022-09-07 The Board of Trustees of the University of Illinois Benzothiophene-based selective estrogen receptor downregulators
MX2019008158A (es) 2017-01-06 2019-12-09 G1 Therapeutics Inc Terapia de combinacion para el tratamiento del cancer.

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2616479C2 (de) * 1976-04-14 1986-12-04 Brickl, Rolf, Dr., 7951 Warthausen Substituierte Fluoracylresorcine, Verfahren zu ihrer Herstellung und diese enthaltende Arzneimittel und Kosmetika
MA19680A1 (fr) * 1982-01-11 1983-10-01 Novartis Ag N- arylsulfonyl - n' - pyrimidinylurees.
SE8400239D0 (sv) * 1984-01-19 1984-01-19 Pharmacia Ab Nya arylettiksyraderivat
JPS6126775A (ja) * 1984-07-16 1986-02-06 Canon Inc 堆積膜形成方法
JPS61144717A (ja) * 1984-12-18 1986-07-02 Canon Electronics Inc ヘツド装置
JPH0683475B2 (ja) * 1985-01-21 1994-10-19 株式会社日立製作所 ビデオテ−プレコ−ダ
JPS61248389A (ja) * 1985-04-24 1986-11-05 松下電工株式会社 照明灯点灯装置
IN164232B (ko) * 1986-04-11 1989-02-04 Hoechst India
JPS62281022A (ja) * 1986-05-30 1987-12-05 Mitsubishi Electric Corp 計算機システムの履歴管理装置
FR2602228A1 (en) * 1986-07-30 1988-02-05 Kirkiacharian Serge New phenoxyisobutyric acids, their derivatives and processes for producing them
HU203515B (en) * 1986-12-12 1991-08-28 Tsumura & Co Process for producing new calcon derivatives and pharmaceutical compositions containing them as active components

Also Published As

Publication number Publication date
RU2125553C1 (ru) 1999-01-27
ATE143935T1 (de) 1996-10-15
HU221007B1 (hu) 2002-07-29
JPH069476A (ja) 1994-01-18
EP0551849B1 (en) 1996-10-09
SK280617B6 (sk) 2000-05-16
SK403692A3 (en) 1995-03-08
ES2093860T3 (es) 1997-01-01
HU9300110D0 (en) 1993-04-28
KR100276933B1 (ko) 2001-02-01
CN1076186A (zh) 1993-09-15
CZ403692A3 (en) 1993-09-15
AU3184793A (en) 1993-07-22
CN1036779C (zh) 1997-12-24
MX9300222A (es) 1993-07-01
DE69305189T2 (de) 1997-03-13
CA2087414A1 (en) 1993-07-17
GR3021338T3 (en) 1997-01-31
DK0551849T3 (da) 1997-03-10
DE69305189D1 (de) 1996-11-14
US5589514A (en) 1996-12-31
TW376382B (en) 1999-12-11
EP0551849A1 (en) 1993-07-21
CA2087414C (en) 2002-04-16
HUT63598A (en) 1993-09-28
CZ285937B6 (cs) 1999-12-15
JP2949000B2 (ja) 1999-09-13
AU662382B2 (en) 1995-08-31
US5776977A (en) 1998-07-07
ZA93267B (en) 1993-08-23

Similar Documents

Publication Publication Date Title
KR930016379A (ko) 아릴사이클로알킬 유도체, 이의 제조방법 및 용도
KR960029325A (ko) 2,8-이치환된 퀴나졸리논
HUT59417A (en) Process for producing azasteroid compounds and pharmaceutical compositions comprising same as active ingredient
AU551239B2 (en) Substituted acyl derivatives of 1,2,3,4-tetrahydro isoquinoline-3-carboxylic acids
IE792027L (en) Pyrroloazetidinones
KR920700209A (ko) 치환된 벤조[5,6]사이클로헵타피리딘의 헤테로사이클릭 n-옥사이드 유도체, 조성물 및 용도
KR910000695A (ko) 3-케토 HMG-CoA리닥타제 억제제
EP0273388A3 (en) Sialic acid derivatives having active carbonyl group
KR860001798A (ko) 플라바논 유도체의 제조방법
KR850007427A (ko) 항균 화합물의 제조방법
US3896166A (en) Formyl-substituted tyrosine
KR860008111A (ko) 인딘과 나프탈렌 유도체의 제조방법
AU599092B2 (en) Novel spergualin-related compounds and process for producing the same
KR960031442A (ko) 페닐시클로헥실카르복스아미드의 용도
KR840005122A (ko) 메틸플라본 유도체의 제조방법
KR880000432A (ko) 4(3H)-옥소-5,6,7,8-테트라히드로피리도-2,3-d 피리미딘 유도체
US4391819A (en) 2,9-Dioxa tricyclo [4,3,1,03,7 ] decane compounds and process of making same
KR940005615A (ko) 시클로헵트이미다졸 유도체, 그의 제조방법 및 이 화합물을 함유하는 치료제
KR880007556A (ko) 새로운 안트라시클린 유도체와 이의 제조 방법
KR920021537A (ko) 벤조피란 유도체와 그의 제조 방법(ii)
KR930023328A (ko) N-메틸데아세틸콜히세인아미드 유도체
GR3020751T3 (en) New 16-alpha steroid-methylation process.
KR910009702A (ko) 크산틴 화합물, 그 제조방법 및 약학적 조성물
KR960000223A (ko) 신규한 피리돈 카르복실산 화합물을 함유한 수용액 및 이의 제조방법
DE69020377T2 (de) Verfahren zur Herstellung von für die Umwelt unbedenklichem Dicofol und dessen Formulierungen.

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
LAPS Lapse due to unpaid annual fee